Prostate Cancer, Version 1.2016
James L. Mohler, Deborah A. Freedman-Cass(National Comprehensive Cancer Network), Eric J. Small(CancerCare Manitoba), Joshua J. Meeks(Northwestern University), Edward M. Schaeffer(Northwestern University), Christopher J. Kane(University of California San Diego), David F. Penson(Geriatric Research Education and Clinical Center), Elizabeth R. Plimack(Fox Chase Cancer Center), Andrew J. Armstrong(Duke University), Richard J. Lee(La Roche College), Brian J. Davis(Southwest Research Institute), Jonathan D. Tward(University of Utah), Julio M. Pow‐Sang(Moffitt Cancer Center), Sylvia Richey(St. Jude Children's Research Hospital), Seth A. Strope(Barnes-Jewish Hospital), Eric M. Horwitz(Fox Chase Cancer Center), Guru Sonpavde(AdventHealth Orlando), Anthony V. D’Amico(Brigham and Women's Hospital), Dorothy A. Shead(University of the Witwatersrand), David Raben(St. Jude Children's Research Hospital), Michael E. Hurwitz(Yale University), Stan Rosenfeld(Office of Patient Care Services), Mack Roach(University of California, San Francisco), Thomas A. Farrington(Health Net), Sandy Srinivas(Stanford University), Charles A. Enke(Susan Thompson Buffett Foundation), Robert R. Bahnson(Fox Chase Cancer Center), Michael Kuettel, Mark H. Kawachi(City of Hope), Celestia S. Higano(University of British Columbia), James A. Eastham(Memorial Sloan Kettering Cancer Center), Ted A. Skolarus(Chicago Department of Public Health)
Cited by 656
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
|New England Journal of Medicine|2010|3.5k
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
|New England Journal of Medicine|2012|2.8k